ArticleJournal of the American Heart Association2026
Implementation of the Get With The Guidelines-Heart Failure Adherence to Science, Implementation in Asia (GWTG-HF A.S.I.A.) Program in Taiwan.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction, yet its adoption across Asia remains suboptimal. The American Heart Association launched the GWTG-HF A.S.I.A. (Get With The Guidelines-Heart Failure Adherence to Science, Implementation in Asia) program in 2021. We examined the association between program participation and GDMT implementation in Taiwan.
methodsWe analyzed 1991 patients with heart failure with reduced ejection fraction enrolled in the Taiwan Society of Cardiology HF Registry (2021-2024). Four hospitals participated in the GWTG-HF A.S.I.A. program (n=462) and 23 nonparticipating hospitals served as controls (n=1529). After propensity-score matching, prescription trends of 4-pillar GDMTs were compared using generalized estimating equations. Primary outcomes were patient-level and hospital-level GDMT prescription rates; secondary outcomes included echocardiographic remodeling, loss to follow-up, and 2-year mortality.
resultsBetween 2021 and 2024, GDMT use increased in both groups, with greater gains in participating hospitals. Adjusted odds ratios (aOR) for program participation were 2.73 (95% CI, 2.23-3.34) for 4-pillar GDMTs, 1.59 (95% CI, 1.31-1.92) for angiotensin receptor-neprilysin inhibitors, 2.06 (95% CI, 1.72-2.47) for SGLT2 (sodium-glucose co-transporter 2) inhibitors, and 1.63 (95% CI, 1.34-2.00) for mineralocorticoid receptor antagonists (all
conclusionsParticipation in the GWTG-HF A.S.I.A. program was associated with higher GDMT prescription rates in Taiwanese hospitals. Structured quality improvement initiatives may help bridge the evidence-practice gap in Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.